Skip to content
Clinical Trials – home

DORZOLAMIDE HYDROCHLORIDE: A Comprehensive Guide for Patients

1 / 2
trials open to patients / all trials
2+
Countries

In short

This article summarizes several clinical trials investigating the use of Dorzolamide Hydrochloride, often in combination with other medications, for treating glaucoma and ocular hypertension. These studies aim to evaluate the efficacy, safety, and tolerability of Dorzolamide Hydrochloride in various formulations and patient populations, including adults and children with different types of glaucoma.

What is Dorzolamide Hydrochloride?

Dorzolamide Hydrochloride is a medication primarily used to treat eye conditions, particularly glaucoma and ocular hypertension (high pressure in the eye). It belongs to a class of drugs called carbonic anhydrase inhibitors. This medication is often referred to by its brand names, which include Trusopt and Cosopt (when combined with another drug called timolol).

Conditions Treated

Dorzolamide Hydrochloride is used to treat several eye conditions, including:

  • Open-Angle Glaucoma: A condition where the eye's drainage channels become clogged over time, leading to increased eye pressure
  • Ocular Hypertension: High pressure within the eye without any detectable changes in vision or damage to the eye structure
  • Cystoid Macular Edema: A condition where fluid accumulates in the central part of the retina (macula), causing swelling
  • Pediatric Glaucoma: Glaucoma that occurs in children

How Dorzolamide Works

Dorzolamide Hydrochloride works by reducing the production of fluid inside the eye. It does this by inhibiting an enzyme called carbonic anhydrase. By decreasing fluid production, the medication helps lower the pressure inside the eye, which is crucial in managing conditions like glaucoma.

In some cases, Dorzolamide may also help improve blood flow to the eye, which can be beneficial for certain eye conditions.

Administration and Dosage

Dorzolamide Hydrochloride is typically administered as eye drops. The usual dosage is one drop in the affected eye(s) three times a day. However, when used in combination with other eye medications, the frequency may be reduced to twice daily. It's important to follow your doctor's instructions carefully and not to change the dosage without consulting them first.

Combination Therapies

Dorzolamide is often used in combination with other eye medications to enhance its effectiveness. Common combinations include:

  • Dorzolamide + Timolol: This combination, often sold under the brand name Cosopt, is frequently used to treat glaucoma and ocular hypertension
  • Dorzolamide + Latanoprost: This combination has been studied for use in pediatric glaucoma
  • Dorzolamide + Timolol + Brimonidine + Bimatoprost: A quadruple combination therapy being studied for its effectiveness in lowering eye pressure

Current Clinical Trials

Several clinical trials are ongoing to further explore the benefits of Dorzolamide Hydrochloride:

  • A study investigating its use in combination with a topical carbonic anhydrase inhibitor to improve central visual function
  • Research on its effectiveness when delivered through drug-eluting contact lenses
  • A trial examining its impact on autoregulation (the eye's ability to maintain stable blood flow) in glaucoma patients
  • An investigation into its potential as an adjuvant therapy after focal photocoagulation in diabetic macular edema

Potential Side Effects

While Dorzolamide Hydrochloride is generally well-tolerated, it may cause some side effects. Common side effects include:

  • Eye irritation or discomfort
  • Blurred vision
  • Bitter taste in the mouth
  • Allergic reactions (in rare cases)

Some studies are specifically looking at the impact of Dorzolamide on dry eye symptoms in patients with glaucoma. If you experience any persistent or severe side effects, it's important to contact your healthcare provider immediately.

Questions people often ask

Conditions where Dorzolamide Hydrochloride is being studied

Each condition opens its own overview and trial list

Trials with Dorzolamide Hydrochloride

Recruiting trials first

See all 2 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).